What is the level of liabilities of Cellectis this year?
Cellectis has a debt balance of 249.57 M USD this year.
Cellectis Liabilities 2024
Cellectis Liabilities
249.57 M USD
Ticker
ALCLS.PA
ISIN
FR0010425595
WKN
A0MKPR
In 2024, Cellectis's total liabilities amounted to 249.57 M USD, a 74.23% difference from the 143.25 M USD total liabilities in the previous year.
Cellectis Aktienanalyse
What does Cellectis do?
Cellectis SA is an emerging biotechnology company focused on developing innovative therapies for cancer and other serious diseases. It was founded in 1999 by a French scientist named André Choulika and is headquartered in Paris, France. Cellectis' main business is the development of CAR-T cell therapies, which involve reprogramming immune cells to target specific types of cancer. This method specifically targets cancer cells while leaving healthy cells unaffected, offering a more precise and less invasive alternative to traditional cancer treatments. Cellectis' business model is centered around developing tailored cancer treatments for individual patients using its Cellectis System, a combination of genomic and cellular technologies. The company also has subsidiaries and joint ventures focusing on different segments of the biopharmaceutical market, such as Calyxt, which specializes in genetic modification of crops, and Ectycell, which focuses on developing cell therapies for rare blood diseases. Cellectis offers a range of products and services focused on cancer drug development, including cell therapies, genetic testing, clinical trials, and consulting services. Its products and services are tailored to the individual needs of patients and aim to revolutionize cancer treatment through advanced technology and innovative approaches. In summary, Cellectis is an innovative biotechnology company successfully focusing on developing tailored cancer therapies. With its wide range of products and services catering to patient needs, and with advancements in cancer therapy, Cellectis is well positioned to become a key player in the biopharmaceutical industry. Cellectis ist eines der beliebtesten Unternehmen auf Eulerpool.com.Liabilities Details
Assessing Cellectis's Liabilities
Cellectis's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Cellectis's financial stability, operational efficiency, and long-term viability.
Year-to-Year Comparison
By comparing Cellectis's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.
Impact on Investments
Cellectis's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.
Interpreting Liability Fluctuations
Shifts in Cellectis’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.
Frequently Asked Questions about Cellectis stock
What were the liabilities of Cellectis compared to the previous year?
The liabilities of Cellectis have increased by 74.23% increased compared to the previous year.
What are the consequences of high debt for investors of Cellectis?
High liabilities can pose a risk for investors of Cellectis, as they can weaken the company's financial position and impair its ability to meet its obligations.
What consequences do low liabilities have for investors in Cellectis?
Low liabilities mean that Cellectis has a strong financial position and is able to meet its obligations without overburdening its finances.
How does an increase in liabilities of Cellectis affect the company?
An increase in liabilities of Cellectis can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.
How does a reduction in the liabilities of Cellectis affect the company?
A decrease in the liabilities of Cellectis can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.
What are some factors that influence the liabilities of Cellectis?
Some factors that can influence the liabilities of Cellectis include investments, acquisitions, operating costs, and sales development.
Why is the level of liabilities of Cellectis so important for investors?
The liabilities of Cellectis are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.
What strategic measures can Cellectis take to modify the liabilities?
To change its liabilities, Cellectis can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.
How much dividend does Cellectis pay?
Over the past 12 months, Cellectis paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Cellectis is expected to pay a dividend of 0 USD.
What is the dividend yield of Cellectis?
The current dividend yield of Cellectis is .
When does Cellectis pay dividends?
Cellectis pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Cellectis?
Cellectis paid dividends every year for the past 0 years.
What is the dividend of Cellectis?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Cellectis located?
Cellectis is assigned to the 'Health' sector.
Wann musste ich die Aktien von Cellectis kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Cellectis from 7/31/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/31/2024.
When did Cellectis pay the last dividend?
The last dividend was paid out on 7/31/2024.
What was the dividend of Cellectis in the year 2023?
In the year 2023, Cellectis distributed 0 USD as dividends.
In which currency does Cellectis pay out the dividend?
The dividends of Cellectis are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The Cellectis stock can be added to a savings plan with the following providers: Trade Republic
Andere Kennzahlen von Cellectis
Our stock analysis for Cellectis Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Cellectis Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
